Yubrine Moraa Gachemba: BETULA Adds New Evidence for Catheter-Directed Thrombolysis in PE
Yubrine Moraa Gachemba, Consultant Cardiologist at The Nairobi Hospital, shared EuroIntervention‘s post on LinkedIn:
“Pulmonary embolism care is entering a more nuanced era.
BETULA adds important randomized evidence that carefully selected patients with intermediate-high-risk PE may achieve earlier right ventricular unloading with low-dose, short-duration catheter-directed thrombolysis, without an observed increase in major bleeding.
But the larger question is not simply whether we can intervene earlier. It is which patients derive meaningful clinical benefit, at what risk, and within which health systems.
For Africa and the wider Global South, this matters enormously. Innovation in PE care must be accompanied by better risk stratification, multidisciplinary decision-making, appropriate imaging, and equitable access to reperfusion strategies.
The future of PE management will not be anticoagulation versus intervention. It will be precision in selecting the right patient, for the right therapy, at the right time.
Important data – and an evolving space to watch.”
EuroIntervention shared a post on LinkedIn about a recent article by Jacob Schultz et al., adding:
“In the randomised BETULA trial, low-dose, short-duration catheter-directed thrombolysis improved early right ventricular unloading compared with anticoagulation alone in patients with intermediate-high-risk pulmonary embolism, without increasing major bleeding.”
Title: Low-dose, short-duration catheter-directed thrombolysis for acute intermediate-high-risk pulmonary embolism: the BETULA trial
Authors: Jacob Schultz, Gro Egholm, Mikael Kjær Poulsen, Bo Løfgren, Morten Würtz, Hanne Maare Søndergaard, Mads Jønsson Andersen, Jacob Valentin Hansen, Gratien Andersen, Shifan Thangavel, Søren Mellemkjær, Anushree Burade, Mannudeep Kalra, Jens Erik Nielsen-Kudsk, Asger Andersen
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 5, 2026, 19:18John R. Mehall: The Importance of Anticoagulation Management in ECMO
-
Sep 5, 2026, 19:16Thirunavukkarasu Angappan: Why Hemophilia B Still Needs Both Plasma-Derived and Recombinant Factor IX
-
Sep 5, 2026, 19:15Michelle Leona Cecil: Comprehensive Hemophilia Care Doesn’t Begin and End With One Appointment
-
Sep 5, 2026, 19:13Amparo Santamaria: Stem Cells and Hematology – Unlocking a New Frontier in Ovarian Regeneration
-
Sep 5, 2026, 19:10Strengthening the Public Health System for Blood Disorders – Hemophilia Federation of America
-
Sep 5, 2026, 19:08Deidra D. Harris: Supporting Hemophilia of Georgia and the Bleeding Disorders Community
-
Sep 5, 2026, 19:06Katherine Blackwell: Blessed to Have the Opportunity to Speak at the Hemophilia of Indiana Annual Meeting
-
Sep 5, 2026, 19:04Christy V.: What You Need to Know about GI Bleeding and Hemophilia
-
Sep 5, 2026, 19:03Dylan Scott: A New Chapter and a Way to Give Back to the Bleeding Disorder Community